The 10 selected trials represent the first stage of clinical evaluations of IMC-A12 NCI under a clinical trials agreement between ImClone Systems and the division of cancer treatment and diagnosis (DCTD), National Cancer Institute.
Both randomized and non-randomized Phase II trials will explore the clinical activity, pharmacology and biological effects of IMC-A12 as a single agent or combined with other relevant anticancer agents in a wide range of malignancies including breast, lung, pancreas and liver cancers, as well as both adult and pediatric sarcomas.
John Johnson, CEO, said: “This NCI program is a great opportunity for ImClone. These NCI-sponsored clinical trials will augment the broad disease-directed phase II program that ImClone has begun for IMC-A12. These studies will also expand our efforts with pediatric cancer patients at a relatively early juncture in IMC-A12's development.”